LizaCoscaVillaruzMD
Oncology • Pittsburgh, PAAssociate Professor, Medicine, University of Pittsburgh School of Medicine
Dr. Villaruz is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
5150 Centre Avenue
Pittsburgh, PA 15232Phone+1 412-623-7833Fax+1 412-648-6579
Education & Training
UPMC Medical EducationFellowship, Hematology and Medical Oncology, 2008 - 2011- UPMC Medical EducationResidency, Internal Medicine, 2005 - 2008
University of Maryland School of MedicineClass of 2005
Certifications & Licensure
PA State Medical License 2005 - 2026
American Board of Internal Medicine Medical Oncology
Clinical Trials
- Detection of Genetic Markers of Lung Cancer
- Stereotactic Radiosurgery or Other Local Ablation Then Erlotinib in Epidermal Growth Factor Receptor (EGFR) Start of enrollment: 2012 Dec 11
- Single Arm on the Tolerability of Weekly Nab-paclitaxel Start of enrollment: 2013 Jun 25
- Join now to see all
Publications & Presentations
PubMed
- Concurrent and Consolidative Carboplatin Plus Nab-Paclitaxel or Paclitaxel in Locally Advanced NSCLC: A Multicenter, Randomized Clinical Trial.Yuanyuan Zhang, Aaron M Laine, Puneeth Iyengar, Kenneth D Westover, Jonathan E Dowell
International Journal of Radiation Oncology, Biology, Physics. 2025-02-06 - Safety and Tolerability of Letetresgene Autoleucel (GSK3377794): Pilot Studies in Patients with Advanced Non-Small Cell Lung Cancer.Mehmet Altan, Gilberto Lopes, T Jeroen N Hiltermann, Ramaswamy Govindan, Liza C Villaruz
Clinical Cancer Research. 2025-02-03 - Phase I trial of ATR inhibitor elimusertib with FOLFIRI in advanced or metastatic gastrointestinal malignancies (ETCTN 10406).Anuradha Krishnamurthy, Hong Wang, John C Rhee, Diwakar Davar, Ryan H Moy
Cancer Chemotherapy and Pharmacology. 2025-01-22
Journal Articles
- PD-L1 Testing in Guiding Patient Selection for PD-1/PD-L1 Inhibitor Therapy in Lung CancerLiza C Villaruz, Mark A Socinski, Molecular Diagnosis & Therapy
Press Mentions
Asymptomatic Brain Metastases in EGFR-Mutant NSCLCDecember 20th, 2024- Treatment of Oligometastatic EGFR-Mutant Lung CancerNovember 22nd, 2024
- Carboplatin, Pemetrexed, and Atezolizumab in Patients with Non-Squamous Non-Small Cell Lung Cancer (NSCLC) and Untreated Brain MetastasesFebruary 27th, 2023
- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
